(fifthQuint)Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients.

 GV1001 0.

56 mg, 1.

12 mg or placebo is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times).

 A total number of administration is 14 times.

 1.

 Control group (placebo): 30 subjects 2.

 Study group 1 (GV1001 0.

56 mg): 30 subjects 3.

 Study group 2 (GV1001 1.

12 mg): 30 subjects.

.

 Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients@highlight

This clinical study is designed as a multi-center, randomized, double-blind, placebo-controlled, parallel design, prospective, phase II clinical trial.

 An eligible subject who meets inclusion and exclusion criteria is randomly assigned to three groups: study group 1 (GV1001 0.

56 mg), study group 2 (GV1001 1.

12 mg) or placebo group.

 A randomized subject is administered either GV1001 or placebo in a total of 14 times and will be evaluated for the efficacy and safety at week of 24.

